Phynova Group
Develops plant-derived health ingredients, including Reducose for blood glucose, for supplement, food and beverage makers
Highlights
- New on EvolcAdded 2026-10-31
About Phynova Group
Phynova Group is a British life science company that identifies, researches and commercialises active ingredients from plants with a history of use in traditional medicine. Its flagship product, Reducose®, is a patented, water-soluble plant-based ingredient for healthy blood glucose, taken as a 250 mg serving alongside meals. The company also builds the scientific, IP and regulatory framework around its ingredients, and its portfolio spans functional ingredients, cosmeceuticals, pharmaceuticals and OTC drugs under the THMP directive.
Reducose® is sold for incorporation into supplements, foods and beverages. The company reports more than 250 million servings sold, availability in over 30 countries, and support from 10+ published clinical trials with five ongoing clinicals.
Phynova states it was founded in Oxford in 2002; the registered company, Phynova Group Ltd, dates from 2004 and is headquartered in Banbury, United Kingdom. Its team combines drug development and regulatory experience with brand development and commercial work.
Product: Reducose®, a patented plant-based functional ingredient for healthy blood glucose, sold for supplements, foods and beverages.
Jobs at Phynova Group
More biotech & pharma companies
Plaquetec
Coronary artery disease endotyping and biomarker discovery for drug developers, using in-vivo plaque samplingNew on EvolcPlethora Solutions
Speciality pharma developing and marketing urology treatments, led by an EU-authorised drug for premature ejaculationNew on EvolcProkarium
Microbial immunotherapy platform built on a proprietary bacterial strain (ZH9) for solid tumour treatmentsNew on EvolcProtein Stable
Microplate instruments for protein characterisation used by scientists in academia and biotechnologyNew on EvolcProveca
Develops and licenses medicines for children with unmet needs in neurology and cardiologyNew on EvolcPsivac
Develops oncolytic adenovirus therapies for cancer patients, targeting solid tumoursNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Google Universal Analytics
- LogRocket
- Mailchimp
- WooCommerce
- WordPress
- jQuery